Clinical impact of NXY-059 demonstrated in the SAINT I trial: Derivation of number needed to treat for benefit over entire range of functional disability

Stroke

Volumn 38, Issue 5, 2007, Pages 1515-1518

  Saver, Jeffrey L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute stroke; Cerebrovascular disease; Clinical trials; Neuroprotective agents; Stroke; Therapy

Indexed keywords

DISUFENTON SODIUM; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CEREBROVASCULAR ACCIDENT; DISABILITY; FUNCTIONAL DISEASE; HUMAN; OUTCOME ASSESSMENT; POPULATION MODEL; PRIORITY JOURNAL; TREATMENT OUTCOME;

BENZENESULFONATES; CARDIOVASCULAR AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CONFIDENCE INTERVALS; HUMANS; NEUROPROTECTIVE AGENTS; SAMPLE SIZE;

EID: 34247643171     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000263135.47779.9e     Document Type: Article

References (11)

1. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ. 1998;316:690-693.
2. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke. 2000;3:1429-1438.
3. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med. 2001;20:3947-3962.
4. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61:1066-1070.
5. Gray LJ, Bath PMW, Collier T; Optimizing Acute Stroke Trials Collaborators. Optimising the statistical analysis of functional outcome in stroke clinical trials. Cerebrovasc Dis. 2005;19(Suppl 2):16. Abstract.
6. Fisher M. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke. 2003;34:1539-1546.
7. Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products. Points to consider on clinical investigation of medicinal products for the treatment of acute stroke. London: European Agency for the Evaluation of Medicinal Products, 2001. Report No.: CPMP/EWP/560/98.
8. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, Sacco RL, Wechsler LR; Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke. 2005;36:1808-1813.
9. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
10. Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making. 2005;25:250-261.
11. Samsa GP, Matchar DB, Goldstein L, Bonito A, Duncan PW, Lipscomb J, Enarson C, Witter D, Venus P, Paul JE, Weinberger M. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998;136:703-713.